Prof. Ugur Sahin, M.D.
Also at Biontech SE
About
As the CEO and Co-Founder of BioNTech, he has been instrumental in transforming the company into a global leader in immunotherapy and vaccine development, driving both research innovation and strategic growth.
His leadership has been marked by significant contributions to advancing oncology pipelines, including the development of mRNA cancer vaccines, antibody-drug conjugates, and CAR-T therapies, as well as the successful commercialization of a COVID-19 vaccine.
In addition to his role in leading breakthrough scientific initiatives, he has championed the integration of artificial intelligence into the discovery process, emphasizing personalized medicine and the development of novel therapeutic solutions.
Although detailed information about his early personal background is limited, his professional journey and ongoing impact at BioNTech underscore his commitment to advancing global healthcare through innovative biotechnology.
$BNTX Performance Under Prof. Ugur Sahin, M.D.
External Roles
Organization | Role | Date Range | Details |
---|---|---|---|
Johannes Gutenberg University, Mainz | Full Professor (W3) in Translational Oncology & Immunology | N/A | Supervised more than 50 Ph.D. students |
Helmholtz Institute for Translational Oncology (HI-TRON), Mainz | Chair of the Scientific Management Board | N/A | N/A |